Drugs Containing Excipient (Inactive Ingredient) MICROCRYSTALLINE CELLULOSE 302

« Back to Dashboard

Branded drugs containing MICROCRYSTALLINE CELLULOSE 302 excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Gilead Sciences Inc	LIVDELZI	seladelpar lysine	61958-3301	MICROCRYSTALLINE CELLULOSE 302	2031-08-14

Generic drugs containing MICROCRYSTALLINE CELLULOSE 302 excipient

Company	Ingredient	NDC	Excipient
WALGREEN CO	esomeprazole magnesium	0363-0361	MICROCRYSTALLINE CELLULOSE 302
Lannett Company LLC	lisdexamfetamine dimesylate	0527-4661	MICROCRYSTALLINE CELLULOSE 302
CVS Pharmacy Inc	esomeprazole magnesium	51316-088	MICROCRYSTALLINE CELLULOSE 302
Aurohealth LLC	esomeprazole magnesium	58602-840	MICROCRYSTALLINE CELLULOSE 302

Microcrystalline Cellulose 302 Market Dynamics and Financial Trajectory

Last updated: October 4, 2026

Microcrystalline cellulose 302, commonly identified as MCC PH 302, is a high-density, directly compressible pharmaceutical excipient used mainly in tablets and hard capsules. Its commercial position is supported by broad regulatory acceptance, established compendial standards, formulation familiarity, and the cost of switching validated tablet processes.

The grade is a specification class rather than a single proprietary product. Competing products include Avicel PH-302, Vivapur 302 and equivalent high-density MCC grades from regional suppliers. Public companies generally report MCC within broader pharmaceutical excipient or nutrition-and-health segments, so standalone revenue, margin and volume data for MCC 302 are not publicly available. The financial outlook is therefore best assessed through pharmaceutical solid-dose growth, excipient pricing, manufacturing capacity, regulatory qualification requirements and supplier concentration.

What is microcrystalline cellulose 302 used for?

MCC 302 is a purified, partially depolymerized cellulose excipient with high bulk density and strong compactability. Compared with lower-density MCC grades such as PH 101, the 302 grade is designed for higher-dose formulations, direct compression and improved die filling.

Attribute	MCC PH 302 commercial relevance
Primary role	Filler, dry binder and compression aid
Main dosage forms	Immediate-release tablets, orally disintegrating tablets, hard capsules
Manufacturing process	Direct compression, wet granulation and dry granulation
Typical performance	High density, good flow, strong tablet binding
Regulatory status	Widely accepted pharmaceutical excipient
Compendial coverage	USP-NF, Ph. Eur. and other national standards, subject to product grade and supplier documentation
Main substitutes	Lactose, mannitol, dibasic calcium phosphate, starch, coprocessed excipients
Main commercial buyers	Generic-drug companies, contract manufacturers and branded-drug manufacturers

MCC 302 is particularly valuable when a formulation requires high tablet weight, reliable powder flow or compression at relatively low lubricant levels. It is also used to improve manufacturability when active pharmaceutical ingredients have poor flow or weak binding properties.

How large is the microcrystalline cellulose market?

Market reports generally place the global microcrystalline cellulose market in the several-hundred-million-dollar range, with estimates differing because some reports include food, nutraceutical and cosmetic grades while others focus on pharmaceutical applications. Published forecasts commonly indicate mid-single-digit annual growth through the end of the decade, driven by pharmaceutical tablets, generic-drug volume and demand for functional excipients (Grand View Research, 2024; MarketsandMarkets, 2024).

The pharmaceutical segment is the highest-value application because it requires tighter specifications, validated supply chains and regulatory documentation. Food and nutraceutical applications contribute significant volume but generally have lower unit economics.

A practical market structure is:

Market layer	Demand profile	Margin profile
Pharmaceutical MCC	Specification-intensive, qualification-driven	Highest
Nutraceutical MCC	Growing tablet and capsule use	Medium
Food MCC	Large-volume stabilizer and bulking applications	Lower
Specialty or coprocessed MCC	Performance-driven formulations	Potentially highest

MCC 302 is a premium pharmaceutical grade rather than a commodity cellulose powder. Its price reflects particle-size distribution, density, moisture, microbial control, batch consistency, documentation, packaging and supplier qualification.

What is the financial trajectory for MCC 302?

The expected financial trajectory is stable to moderately positive, with volume growth likely to exceed pricing growth. The category has limited exposure to abrupt patent-cycle risk because MCC 302 is an input used across many products rather than an active pharmaceutical ingredient tied to one brand.

Revenue drivers

The main revenue drivers are:

1. Growth in generic tablets and capsules.
2. Expansion of contract development and manufacturing organizations.
3. Continued use of direct compression to reduce manufacturing steps.
4. Higher demand for high-dose tablets.
5. Growth in nutraceutical tablets and hard capsules.
6. Increased outsourcing of excipient manufacturing and formulation development.
7. Demand for reliable supply after pharmaceutical supply-chain disruptions.

Generic drug production is the most important underlying demand factor. Most generic tablets use established excipient systems, and MCC remains one of the most widely used direct-compression binders.

Margin drivers

MCC 302 margins depend on manufacturing scale and access to consistent cellulose feedstock. The main cost inputs include purified cellulose, energy, water, labor, packaging, quality control and logistics.

Premium pricing is supported by:

• Validated manufacturing processes.
• Long customer qualification cycles.
• Multi-site quality documentation.
• Low tolerance for batch variability.
• Regulatory change-control obligations.
• Technical support during formulation and scale-up.

Pricing power is limited by the availability of alternative MCC suppliers and substitute excipients. Large pharmaceutical buyers can negotiate volume contracts, while smaller customers may pay more for technical support, smaller batch quantities and shorter lead times.

Base-case outlook

Period	Expected market condition	Financial implication
Near term	Stable pharmaceutical tablet demand, continued cost scrutiny	Low-to-mid-single-digit revenue growth
Medium term	Generic-volume expansion and contract manufacturing growth	Positive volume growth with moderate price pressure
Longer term	Greater use of coprocessed and engineered excipients	Mixed outlook for standard MCC 302; stronger outlook for differentiated grades

Standard MCC 302 should experience lower growth than novel coprocessed excipients, but it is likely to retain a larger installed base. Its established regulatory history reduces technical adoption risk.

Which companies supply MCC 302?

The principal competitive set includes multinational excipient manufacturers and regional suppliers with pharmaceutical-grade cellulose capacity.

Supplier or product family	Relevant commercial position
IFF, including legacy Avicel pharmaceutical excipient operations	Avicel PH grades, including high-density MCC products
JRS Pharma	Vivapur MCC grades, including Vivapur 302
DFE Pharma	Pharmaceutical excipient portfolio and direct-compression systems
Roquette	Cellulose and functional excipient products, depending on market and grade
Regional cellulose manufacturers	Lower-cost alternatives, often competing on price and local availability

Product naming and ownership can vary by geography, distributor and corporate transaction history. Buyers must verify the current legal manufacturer, manufacturing site, specification and regulatory package for each marketed grade.

Competitive differentiation increasingly depends on more than basic compliance with MCC monographs. Suppliers compete on:

• Consistent bulk density.
• Narrow particle-size distribution.
• Low moisture variability.
• Tablet tensile strength.
• Disintegration performance.
• Lubricant sensitivity.
• Container-closure options.
• Regional inventory.
• Change-control execution.
• Technical formulation support.

What formulations are protected by MCC 302?

MCC 302 itself is usually protected through trade secrets, manufacturing know-how, quality systems and product specifications rather than enforceable product patents. The underlying substance, microcrystalline cellulose, is old and broadly described in the scientific and patent literature.

Potentially protectable areas include:

• Specific particle-size distributions.
• Density ranges.
• Moisture levels.
• Porosity and compressibility profiles.
• Surface-treated MCC.
• Coprocessed MCC systems.
• MCC combined with lactose, mannitol, starch or other binders.
• Manufacturing methods that produce defined functionality.
• Formulation-specific tablet compositions.

A supplier may hold patents covering a differentiated excipient or manufacturing process, but routine MCC PH 302 does not generally create an Orange Book-style exclusivity position.

What is the FDA regulatory status of MCC 302?

The FDA does not approve excipients through the same premarket approval pathway used for active pharmaceutical ingredients. MCC is accepted through its use in approved drug products, compliance with applicable standards and supplier documentation.

The FDA Inactive Ingredient Database lists microcrystalline cellulose across numerous approved drug products and routes of administration. The relevant regulatory assessment depends on the exact grade, route, dosage form, maximum daily exposure and intended use (U.S. Food and Drug Administration, 2024).

Key regulatory considerations include:

• Identity and purity testing.
• Particle-size and bulk-density control.
• Microbial limits.
• Residual processing chemicals.
• Heavy metals and elemental impurities.
• Water content.
• Supplier change control.
• Good manufacturing practice.
• Compendial compliance.
• Extractables and leachables where packaging creates risk.

European pharmaceutical users typically assess MCC against the European Pharmacopoeia and applicable excipient-manufacturing expectations. The European Medicines Agency also expects manufacturers to apply appropriate risk management to excipient quality and supply chains (European Medicines Agency, 2015).

Does MCC 302 have Orange Book exclusivity or Paragraph IV risk?

MCC 302 has no Orange Book listing as an active drug and does not have drug-product exclusivity. It is an excipient, not a medicinal active ingredient.

Paragraph IV litigation generally concerns patents listed for an approved drug in the FDA Orange Book. A generic company using MCC 302 may face patent risk from the finished dosage form, formulation, manufacturing process or method of use, but that risk normally arises from the drug product rather than the MCC grade itself.

Legal issue	Relevance to MCC 302
Orange Book listing	None for MCC as an excipient
Paragraph IV certification	Applies to listed drug patents, not routine excipient use
Formulation patent	May cover a finished tablet containing MCC
Process patent	May cover granulation, compression or tablet manufacture
Trade-secret risk	Important for supplier manufacturing know-how
Supplier qualification	Major commercial barrier to substitution

How strong is the intellectual-property position for MCC 302?

The basic patent position is weak because microcrystalline cellulose is an established excipient with extensive prior art. The commercial protection is stronger than the basic composition protection.

Sources of practical protection

Supplier defensibility primarily comes from:

• Manufacturing consistency.
• Proprietary process parameters.
• Scale and cost position.
• Regulatory history.
• Customer qualification.
• Global quality systems.
• Reliable supply of pharmaceutical-grade cellulose.
• Formulation support.

A competitor can make a chemically similar product but still face a lengthy qualification process. Pharmaceutical manufacturers may need comparative characterization, development batches, stability data, process validation and regulatory submissions before switching suppliers.

This creates a qualification moat rather than a classic patent moat.

What manufacturing barriers affect MCC 302 supply?

The largest barriers are operational and regulatory.

Raw-material control

MCC is produced from highly purified cellulose, often derived from wood pulp or other plant-based cellulose sources. Feedstock quality affects ash, fiber structure, degree of polymerization, moisture and impurity levels.

Process consistency

Hydrolysis, washing, drying, milling and classification determine the final grade. Small changes can affect:

• Flowability.
• Tablet tensile strength.
• Ejection force.
• Disintegration.
• Lubricant sensitivity.
• Bulk density.
• Filling performance.

Pharmaceutical qualification

A new supplier must usually provide a technical package covering manufacturing sites, specifications, analytical methods, stability, impurities, change-control policy and regulatory support. Customers may conduct audits and run comparative tablet studies.

Supply-chain concentration

The market has several major suppliers, but pharmaceutical-grade capacity is less fungible than ordinary cellulose capacity. A disruption at one qualified site may not be quickly replaceable because alternative products require testing and approval.

What generic launch risks are linked to MCC 302?

MCC 302 does not determine generic launch timing in the way an API patent does. Its impact is operational.

Generic manufacturers face five main risks:

1. The selected MCC grade may alter tablet hardness or dissolution.
2. A supplier change may require additional development work.
3. Density differences may affect tablet weight and die filling.
4. Moisture changes may affect stability and compression.
5. A formulation patent may claim a specific excipient combination.

For immediate-release products, switching among equivalent MCC grades may be manageable. For modified-release, orally disintegrating or high-dose tablets, the excipient can have a greater effect on critical quality attributes.

How does MCC 302 compare with alternative excipients?

Excipient	Relative advantage versus MCC 302	Relative limitation
Lactose monohydrate	Low cost and broad availability	Lower binding performance in some formulations; incompatibility concerns with some APIs
Mannitol	Good mouthfeel and useful for chewables	Higher cost and different compaction behavior
Dibasic calcium phosphate	High density and low hygroscopicity	Brittle deformation; less suitable for some formulations
Pregelatinized starch	Binding and disintegration functionality	More variable moisture and flow behavior
Coprocessed excipients	Improved functionality and process performance	Higher cost and narrower supplier base
MCC PH 101	Strong binding and broad historical use	Lower density and poorer fit for high-dose direct compression
MCC PH 302	High density and strong direct-compression performance	Can require optimization for disintegration and lubrication

MCC 302 is strongest where density, flow and compactability are priorities. It is less differentiated when the formulation needs rapid disintegration, extreme moisture protection or specialized modified-release behavior.

What licensing and partnership activity affects MCC 302?

MCC 302 is sold primarily through supplier distribution, technical agreements and long-term procurement relationships rather than conventional pharmaceutical licensing deals. Commercial arrangements may include:

• Regional distribution agreements.
• Private-label supply.
• Dual-sourcing contracts.
• Technology-transfer arrangements.
• Contract manufacturing of equivalent grades.
• Joint development of coprocessed excipients.
• Strategic supply agreements with generic-drug manufacturers.

These agreements are often private. Public company filings usually disclose broader excipient or nutrition-and-health revenue rather than individual MCC grades.

The most valuable commercial relationships are those that place a supplier on a customer’s approved-material list. Once qualified, a supplier may retain business for years unless price, quality or supply reliability deteriorates.

What is the geographic outlook for MCC 302?

Demand is concentrated in North America, Europe, India and China, with growth increasingly tied to emerging pharmaceutical manufacturing hubs.

Region	Market characteristics
North America	Mature generic and branded tablet market; high documentation standards
Europe	Strong compendial and quality requirements; established excipient suppliers
India	Large generic manufacturing base and strong price sensitivity
China	Expanding pharmaceutical production and domestic excipient capacity
Latin America	Import exposure and growing generic-drug demand
Southeast Asia	Contract manufacturing and pharmaceutical production expansion

Local production can improve lead times and reduce import exposure, but pharmaceutical customers still prioritize consistent quality and regulatory history. Regional suppliers may gain share in price-sensitive markets, while multinational suppliers retain an advantage in global submissions and multinational account management.

What is the investment outlook for MCC 302?

MCC 302 is a defensive excipient category with moderate growth, limited patent-cycle volatility and relatively predictable demand. It is unlikely to produce the growth rates associated with novel drug delivery systems or specialty biologic excipients.

The investment case depends on:

• Pharmaceutical excipient capacity utilization.
• Exposure to generic-drug volumes.
• Raw-material and energy costs.
• Ability to pass through inflation.
• Share of premium grades and coprocessed products.
• Geographic manufacturing footprint.
• Customer concentration.
• Quality-event history.
• Supply agreements and qualification depth.

Standard MCC 302 has a stable volume outlook but limited pricing expansion. Higher returns are more likely in differentiated grades, engineered particles and coprocessed systems that solve specific compression, flow or disintegration problems.

Key Takeaways

• MCC 302 is a high-density, directly compressible microcrystalline cellulose grade used mainly in tablets and capsules.
• Its demand is tied to generic-drug production, direct compression and solid-dose manufacturing.
• Public companies do not normally disclose standalone revenue or margins for MCC 302.
• The global MCC market is generally expected to grow at a mid-single-digit rate, although published estimates vary by market definition.
• Standard MCC 302 has limited composition-patent protection. Its main commercial defenses are qualification, quality consistency, manufacturing know-how and supply reliability.
• MCC 302 has no Orange Book exclusivity and does not create standalone Paragraph IV risk.
• The strongest competitive opportunities are in premium, coprocessed and engineered excipients rather than undifferentiated MCC.
• Financial performance should be relatively stable, with moderate volume growth and continuing price pressure from alternative suppliers and excipients.

FAQs About Microcrystalline Cellulose 302

Is MCC PH 302 the same as Avicel PH-302?

They are comparable high-density MCC grades, but they are not automatically identical. Particle-size distribution, density, moisture, compressibility and manufacturing site must be compared through supplier specifications and formulation testing.

Can MCC 302 be used in direct compression?

Yes. Direct compression is one of its principal applications. Its high density and binding capacity make it suitable for tablets requiring reliable die filling and compaction.

Is microcrystalline cellulose 302 safe for pharmaceutical use?

MCC is widely used in approved pharmaceutical products and is recognized in major pharmacopoeias. Safety and suitability still depend on grade, route, dosage, impurity controls and compliance with the applicable specification.

Can a pharmaceutical manufacturer switch from MCC PH 101 to PH 302?

Yes, but the change requires formulation and process assessment. The higher density of PH 302 can alter tablet weight, powder flow, compression force, hardness, disintegration and dissolution.

Does MCC 302 affect tablet dissolution?

It can. MCC influences porosity, water penetration, tablet hardness and disintegration. The effect depends on concentration, compression force, lubricant level, active ingredient properties and the rest of the excipient system.

References

European Medicines Agency. (2015). Guideline on the risk assessment of excipients in medicinal products for human use. EMA.

Grand View Research. (2024). Microcrystalline cellulose market size, share and trends analysis report. Grand View Research.

MarketsandMarkets. (2024). Microcrystalline cellulose market by source, application and region: Global forecast. MarketsandMarkets.

U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.